Importer of Controlled Substances Application: Sharp Clinical Services, LLC, 19988 [2023-06948]
Download as PDF
19988
Federal Register / Vol. 88, No. 64 / Tuesday, April 4, 2023 / Notices
Dated: March 30, 2023.
Thomas V. Curtin, Jr.,
Executive Director, Joint Board for the
Enrollment of Actuaries.
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on February 8, 2023, Sharp
Clinical Services, LLC, 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020–
8024, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
[FR Doc. 2023–06977 Filed 4–3–23; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
code
Controlled substance
[Docket No. DEA–1160]
Importer of Controlled Substances
Application: Sharp Clinical Services,
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Gamma Hydroxybutyric Acid
3,4Methylenedioxymethamphetamine.
5-Methoxy-N-Ndimethyltryptamine.
Schedule
2010
7405
I
I
7431
I
AGENCY:
Sharp Clinical Services, LLC
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 4, 2023. Such persons
may also file a written request for a
hearing on the application on or before
May 4, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:41 Apr 03, 2023
Jkt 259001
The company plans to import the
listed controlled substances for
distribution and clinical trials. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023–06948 Filed 4–3–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on January 28, 2023,
SpecGX LLC, 3600 North 2nd Street,
Saint Louis, Missouri 63147, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Drug Enforcement Administration
[Docket No. DEA–1177]
Importer of Controlled Substances
Application: SpecGX LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
SpecGX, LLC has applied to
be registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplemental Information
listed below for further drug
information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 4, 2023. Such persons
may also file a written request for a
hearing on the application on or before
May 4, 2023.
ADDRESSES: The Drug Enforcement
Administration (DEA) requires that all
SUMMARY:
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Marihuana .....................
Phenylacetone ..............
Coca Leaves ................
Thebaine .......................
Opium, Raw ..................
Poppy Straw Concentrate.
Tapentadol ....................
Drug
code
Schedule
7360
8501
9040
9333
9600
9670
I
II
II
II
II
II
9780
II
The company plans to import the
listed controlled substances for bulk
manufacture into Active Pharmaceutical
Ingredients (API) for distribution to its
customers. In reference to Tapentadol
(9780) and Thebaine (9333), the
company plans to import intermediate
forms of these controlled substances for
further manufacturing prior to
distribution to its customers. In
reference to drug code 7360
(Marihuana), the company plans to
import synthetic cannabinol. No other
activity for this drug is authorized for
this registration. Placement of these
codes onto the company’s registration
does not translate into automatic
approval of subsequent permit
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 88, Number 64 (Tuesday, April 4, 2023)]
[Notices]
[Page 19988]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06948]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1160]
Importer of Controlled Substances Application: Sharp Clinical
Services, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sharp Clinical Services, LLC has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
May 4, 2023. Such persons may also file a written request for a hearing
on the application on or before May 4, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on February 8, 2023, Sharp Clinical Services, LLC, 2400
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
3,4-Methylenedioxymethamphetamine...... 7405 I
5-Methoxy-N-N-dimethyltryptamine....... 7431 I
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
distribution and clinical trials. No other activities for these drug
codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-06948 Filed 4-3-23; 8:45 am]
BILLING CODE 4410-09-P